Dr. Isaac A. Bowman, MD
Medical Oncology (Medical Oncology Physician)
2946 E Banner Gateway Dr
Gilbert, AZ 85234
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 309
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: University of Texas Southwestern Medical School at Dallas
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
AZ license 62482
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Banner Thunderbird Medical Center Glendale, AZ
- Banner Gateway Medical Center Gilbert, AZ
- Banner Baywood Medical Center Mesa, AZ
Medical groups
- Banner Cancer Center Specialists LLC (344 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 309
- Services billed
- 857
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 432 | 154 |
| Established patient office or other outpatient visit, 30-39 minutes | 262 | 160 |
| New patient office or other outpatient visit, 60-74 minutes | 69 | 69 |
| Telephone medical discussion with physician, 21-30 minutes | 53 | 40 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 37 | 29 |
| Telephone medical discussion with physician, 11-20 minutes | 22 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 176 |
| Prednisone Other prescribers in Gilbert, AZ | 122 |
| Abiraterone Acetate | 111 |
| Gabapentin Other prescribers in Gilbert, AZ | 62 |
| Tamsulosin Hcl Other prescribers in Gilbert, AZ | 55 |
| Dexamethasone Other prescribers in Gilbert, AZ | 52 |
| Nubeqa (darolutamide) | 44 |
| Xtandi (enzalutamide) | 43 |
| Prochlorperazine Maleate Other prescribers in Gilbert, AZ | 43 |
| Cabometyx (cabozantinib s-malate) | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 10 payments worth $5,759 in total to this clinician.
| Pfizer Inc. | $5,413 |
|---|---|
| Janssen Biotech, Inc. | $125 |
| AstraZeneca Pharmaceuticals LP | $85.00 |
| Caris Mpi, Inc. | $53.85 |
| Aveo Pharmaceuticals, Inc. | $41.76 |
| Novartis Pharmaceuticals Corporation | $26.00 |
| Ferring Pharmaceuticals Inc. | $14.95 |
| Consulting Fee | $5,280 |
|---|---|
| Food and Beverage | $394 |
| Education | $85.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Jan 29, 2025 | Consulting Fee PADCEV · ONCOLOGY | $2,880 |
| Pfizer Inc. Jun 17, 2025 | Consulting Fee TALZENNA · ONCOLOGY | $2,400 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Education LYNPARZA · Oncology · in-kind Company’s descriptionEducational Item | $85.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $218,283 in research payments for these studies, mostly to the institutions running them.
- A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Ca…
AstraZeneca Pharmaceuticals LP - A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
E.r. Squibb & Sons, L.l.c. - A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigators Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants…
Celgene Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.